Skip to main content

SARS-CoV2 Infection

7
Pipeline Programs
9
Companies
8
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
4
1
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
267%
Vaccine
133%
+ 7 programs with unclassified modality

Competitive Landscape

9 companies ranked by most advanced pipeline stage

Biocorp
BiocorpFrance - Issoire
2 programs
1
1
SARS-CoV-2 vaccinePhase 3Vaccine1 trial
HDT-301Phase 11 trial
Active Trials
NCT05132907Completed48Est. May 2024
NCT04508075Completed1,620Est. Aug 2021
Bharat Biotech
Bharat BiotechIndia - Hyderabad
1 program
1
COVAXINPhase 2/31 trial
Active Trials
NCT04918797Completed525Est. Jan 2022
Dermama Bioteknologi Laboratorium
1 program
1
Exosome-MSC Intravenous injectionPhase 2/31 trial
Active Trials
NCT05216562Unknown60Est. Dec 2022
Kalbe
KalbeIndonesia - Jakarta
1 program
1
GX-19NPhase 2/3
Genexine
GenexineKorea - Seoul
1 program
1
GX-19NPhase 2/31 trial
Active Trials
NCT05067946Withdrawn0Est. Oct 2023
Immunome
ImmunomePA - Exton
1 program
1
IMM-BCP-01Phase 11 trial
Active Trials
NCT05429021Terminated9Est. Jan 2023
Gilead Sciences
Gilead SciencesFOSTER CITY, CA
1 program
RemdesivirN/ASmall Molecule
Kite Pharma
Kite PharmaCA - El Segundo
1 program
RemdesivirN/ASmall Molecule1 trial
Active Trials
NCT04323761Approved For Marketing
Biomed
BiomedAustralia - Sydney
1 program
TekiTrust Tests to Determine the Level of SARS-COV-2/COVID-19 Neutralizing Antibodies in the BloodN/A1 trial
Active Trials
NCT05338762Completed218Est. Aug 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
BiocorpSARS-CoV-2 vaccine
GenexineGX-19N
Dermama Bioteknologi LaboratoriumExosome-MSC Intravenous injection
Bharat BiotechCOVAXIN
ImmunomeIMM-BCP-01
BiocorpHDT-301
BiomedTekiTrust Tests to Determine the Level of SARS-COV-2/COVID-19 Neutralizing Antibodies in the Blood

Clinical Trials (8)

Total enrollment: 2,480 patients across 8 trials

NCT04508075BiocorpSARS-CoV-2 vaccine

Efficacy, Safety and Immunogenicity Study of SARS-CoV-2 Inactivated Vaccine

Start: Aug 2020Est. completion: Aug 20211,620 patients
Phase 3Completed

Evaluation of Efficacy, Safety and Immunogenicity of GX-19N in Healthy Individuals Who Have Received COVID-19 Vaccines

Start: Oct 2021Est. completion: Oct 20230
Phase 2/3Withdrawn
NCT05216562Dermama Bioteknologi LaboratoriumExosome-MSC Intravenous injection

Efficacy and Safety of EXOSOME-MSC Therapy to Reduce Hyper-inflammation In Moderate COVID-19 Patients

Start: Jul 2021Est. completion: Dec 202260 patients
Phase 2/3Unknown

COVAXIN in a Pediatric Cohort

Start: May 2021Est. completion: Jan 2022525 patients
Phase 2/3Completed

IMM-BCP-01 in Mild to Moderate COVID-19

Start: Jun 2022Est. completion: Jan 20239 patients
Phase 1Terminated

Safety and Immunogenicity of HDT-301 Targeting a SARS-CoV-2 Variant Spike Protein

Start: Jan 2022Est. completion: May 202448 patients
Phase 1Completed

Expanded Access Treatment Protocol: Remdesivir (RDV; GS-5734) for the Treatment of SARS-CoV2 (CoV) Infection (COVID-19)

N/AApproved For Marketing
NCT05338762BiomedTekiTrust Tests to Determine the Level of SARS-COV-2/COVID-19 Neutralizing Antibodies in the Blood

TekiTrust Tests to Determine the Level of SARS-COV-2/COVID-19 Neutralizing Antibodies in the Blood

Start: Jun 2021Est. completion: Aug 2022218 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
9 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.